EcoDrugPlus

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSCVAG00000021680
Gene Symbol: LOC107083403
3 Cross references
176 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSCVAG00000004142
Gene Symbol: LOC107094519
3 Cross references
175 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSCVAG00000005996
Gene Symbol: AOC1
3 Cross references
233 Possible Orthologues:

Amine Oxidase Copper Containing 2

Ensembl ID : ENSCVAG00000018158
Gene Symbol: AOC2
1 Cross references
400 Possible Orthologues:

Amyloid Beta A4 Protein-Like

Ensembl ID : ENSCVAG00000008356
Gene Symbol: LOC107104503
3 Cross references
205 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSCVAG00000019775
Gene Symbol: APP
4 Cross references
206 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSCVAG00000003579
Gene Symbol: AR
4 Cross references
214 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSCVAG00000004805
Gene Symbol: AR
2 Cross references
205 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSCVAG00000000446
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:

Anti-Apoptotic Protein Nr13-Like

Ensembl ID : ENSCVAG00000015872
Gene Symbol: LOC107099435
3 Cross references
129 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSCVAG00000007368
Gene Symbol: APLNR2
1 Cross references
172 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSCVAG00000017756
Gene Symbol: LOC107080667
2 Cross references
142 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).